Stay updated with breaking news from After Meniere. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The strongest catalysts for a pharma stock are the various milestones on the road to FDA approval for new drugs. For new investors, they’ll often see a stock rise astronomically, but, when they go to make sense of the reasons for the jump, they’re greeted with unfamiliar acronyms. Let... Read More...
BioXcel Therapeutics Inc (NASDAQ: BTAI) plans to finalize study design, dosing, and endpoints for its BXCL501 Phase 3 program in dementia-related agitation. The end of the Phase 2 meeting with the FDA is scheduled in Q2 2021. BXCL501 is an orally dissolving thin film formulation of... Read More...